DIFICID Drug Patent Profile

Which patents cover Dificid, and when can generic versions of Dificid launch?

Dificid is a drug marketed by Cubist Pharms Llc and is included in two NDAs. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and fifty-eight patent family members in thirty-six countries.

The generic ingredient in DIFICID is fidaxomicin. There are two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the fidaxomicin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Dificid

A generic version of DIFICID was approved as fidaxomicin by ACTAVIS LABS FL on January 16^th, 2024.

Summary for DIFICID

International Patents:	158
US Patents:	5
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DIFICID

Paragraph IV (Patent) Challenges for DIFICID

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DIFICID	Tablets	fidaxomicin	200 mg	201699	1	2015-05-27

US Patents and Regulatory Information for DIFICID

DIFICID is protected by five US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cubist Pharms Llc	DIFICID	fidaxomicin	FOR SUSPENSION;ORAL	213138-001	Jan 24, 2020		RX	Yes	Yes	9,808,530*PED				Y
Cubist Pharms Llc	DIFICID	fidaxomicin	TABLET;ORAL	201699-001	May 27, 2011	AB	RX	Yes	Yes	7,378,508*PED				Y
Cubist Pharms Llc	DIFICID	fidaxomicin	FOR SUSPENSION;ORAL	213138-001	Jan 24, 2020		RX	Yes	Yes	7,863,249*PED				Y
Cubist Pharms Llc	DIFICID	fidaxomicin	TABLET;ORAL	201699-001	May 27, 2011	AB	RX	Yes	Yes	7,863,249*PED				Y
Cubist Pharms Llc	DIFICID	fidaxomicin	FOR SUSPENSION;ORAL	213138-001	Jan 24, 2020		RX	Yes	Yes	7,378,508*PED				Y
Cubist Pharms Llc	DIFICID	fidaxomicin	FOR SUSPENSION;ORAL	213138-001	Jan 24, 2020		RX	Yes	Yes	7,906,489*PED				Y

International Patents for DIFICID

See the table below for patents covering DIFICID around the world.

Country	Patent Number	Title	Estimated Expiration
Cyprus	1121459
Spain	2713954
Poland	2305245
Slovenia	1539977
Japan	5734545
Denmark	2070530

Supplementary Protection Certificates for DIFICID

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1539977	2015/019	Ireland		PRODUCT NAME: FIDAXOMICIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NAT REGISTRATION NO/DATE: EU/1/11/733/001-004 20111205; FIRST REGISTRATION NO/DATE: EU/1/11/733/001-004 20111205
1539977	585	Finland
1539977	C300727	Netherlands		PRODUCT NAME: FIDAXOMICINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/733/001-004 20111205
1539977	300727	Netherlands		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), MERGE
1539977	C20150013 00220	Estonia		PRODUCT NAME: FIDAKSOMITSIIN;REG NO/DATE: EU/1/11/733 07.12.2011
1539977	C 2015 015	Romania		PRODUCT NAME: FIDAXOMICIN; NATIONAL AUTHORISATION NUMBER: EU/1/11/733/001, EU/1/11/733/002, EU/1/11/733/003, EU/1/11/733/004; DATE OF NATIONAL AUTHORISATION: 20111205; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/733/001, EU/1/11/733/002, EU/1/11/733/003, EU/1/11/733/004; DATE OF FIRST AUTHORISATION IN EEA: 20111205

DIFICID: Patent Landscape and Investment Fundamentals

Last updated: February 19, 2026

DIFICID (fidaxomicin) is an antibiotic used for treating Clostridioides difficile infection (CDI). The drug's patent landscape, market exclusivity, and ongoing clinical developments inform its investment outlook. Key patents governing DIFICID are expiring, opening the door for generic competition.

What is the Core Technology Behind DIFICID?

DIFICID's active pharmaceutical ingredient is fidaxomicin. Fidaxomicin is a macrocyclic antibiotic. It inhibits RNA polymerase in bacteria, halting protein synthesis. This mechanism of action is distinct from many other antibiotics used for CDI, such as vancomycin. Fidaxomicin targets C. difficile bacteria while having a less disruptive effect on the gut microbiome. [1]

What is the Regulatory Status of DIFICID?

DIFICID received U.S. Food and Drug Administration (FDA) approval on May 25, 2011, for the treatment of CDI in patients 18 years of age or older. [2] The European Medicines Agency (EMA) granted marketing authorization in Europe in August 2011. [3] DIFICID is marketed by Merck & Co. in the United States.

What are the Key Patents Protecting DIFICID?

The original patent for fidaxomicin was filed by Optimer Pharmaceuticals. Key patents covering DIFICID include:

• U.S. Patent No. 7,041,671: Titled "Macrocyclic compounds and their use as antibacterials," this patent covers fidaxomicin and its use in treating bacterial infections. The earliest priority date for this patent family is November 21, 2002. [4]
• U.S. Patent No. 7,531,548: Titled "Novel macrocyclic compounds and their use as antibacterials," this patent is a continuation of the '671 patent and was issued on May 12, 2009. [5]
• U.S. Patent No. 8,178,085: Titled "Formulations of macrocyclic compounds," this patent covers specific pharmaceutical formulations of fidaxomicin. It was issued on May 15, 2012. [6]

The base patents protecting the composition of matter for fidaxomicin have either expired or are nearing expiration. For instance, U.S. Patent No. 7,041,671 expired in November 2023. [4] Formulation patents, such as U.S. Patent No. 8,178,085, may offer extended protection, typically until around 2032, depending on specific patent term extensions and challenges. [6]

What is the Market Exclusivity Status for DIFICID?

Beyond patent protection, regulatory exclusivities contribute to market exclusivity. DIFICID was granted five years of New Chemical Entity (NCE) exclusivity by the FDA upon its initial approval in 2011. This NCE exclusivity expired in May 2016. [2] Orphan drug exclusivity, if applicable, could extend this period. However, CDI is not typically considered a rare disease that would qualify for orphan drug designation in most jurisdictions.

Who are the Main Competitors in the CDI Treatment Market?

The competitive landscape for CDI treatment includes:

• Oral Vancomycin: This has been a standard treatment for CDI for decades. It is available generically.
• Metronidazole: Another older antibiotic sometimes used for mild CDI cases, also available generically.
• Bezlotoxumab (Zinplava): A monoclonal antibody that neutralizes C. difficile toxin B, approved in 2016. It is used in conjunction with antibiotics to prevent recurrence in patients at high risk of recurrence. [7]
• Ibrexafungerp (Nurxsa): Approved in 2021, this is an orally available triterpenoid antifungal with activity against C. difficile. [8]
• Generic Fidaxomicin: As the core composition of matter patents expire, generic versions of fidaxomicin are entering or are expected to enter the market. For example, generic fidaxomicin 200 mg tablets received tentative approval from the FDA in late 2023. [9]

What is the Projected Market Size for CDI Treatments?

The global CDI therapeutics market was valued at approximately USD 1.5 billion in 2022 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 3-5% through 2030. [10] Factors driving market growth include an aging population, increased use of broad-spectrum antibiotics, and rising rates of hospital-acquired infections. The introduction of generic fidaxomicin is expected to increase market volume but potentially reduce overall market revenue in the short term.

What are the Key Clinical Trial Data for DIFICID?

DIFICID's initial approval was based on two pivotal Phase 3 clinical trials (Study 105 and Study 106). These randomized, double-blind, non-inferiority trials compared fidaxomicin 200 mg twice daily for 10 days to vancomycin 125 mg four times daily for 10 days. [11]

Key findings from these trials:

• Sustained Clinical Response: DIFICID demonstrated a sustained clinical response rate (defined as resolution of diarrhea and no need for further CDI treatment for 20 days after end of therapy) in 79.5% of patients compared to 75.9% for vancomycin. [11]
• Recurrence Rates: DIFICID showed a significantly lower rate of CDI recurrence within 30 days of treatment completion compared to vancomycin. The recurrence rate was 13.3% for DIFICID versus 17.5% for vancomycin. [11] This reduction in recurrence is a significant differentiator.
• Microbiome Impact: Post-hoc analyses indicated that DIFICID had a less detrimental impact on the gut microbiome compared to vancomycin, potentially contributing to lower recurrence rates. [12]

Ongoing research and post-marketing studies continue to evaluate DIFICID's efficacy in specific patient populations and against emerging strains of C. difficile.

What are the Pricing and Reimbursement Dynamics?

DIFICID's pricing has historically been at a premium compared to generic vancomycin, reflecting its novel mechanism and improved recurrence profile. The wholesale acquisition cost (WAC) for a 10-day course of DIFICID has been in the range of USD 3,000-4,000. [13]

Reimbursement is generally favorable for patients with moderate to severe CDI, especially those at high risk of recurrence, due to the documented clinical benefits. However, the introduction of generics is expected to exert downward pressure on pricing. Payer formularies will likely adapt to include generic fidaxomicin, potentially as a first-line option in certain scenarios, leading to increased utilization but lower per-unit revenue for the originator product.

What are the Risks and Opportunities for Investors?

Risks:

• Generic Competition: The primary risk is the imminent or ongoing market entry of generic fidaxomicin products, which will erode market share and pricing power for the originator.
• Market Saturation: The CDI treatment market, while growing, is subject to the introduction of new therapeutic modalities and increasing competition.
• Antibiotic Resistance: While fidaxomicin has a lower risk of resistance development compared to some antibiotics, the long-term emergence of resistance is an ongoing concern in antibiotic therapy.
• Off-Label Use and Off-Patent Competition: Existing generic antibiotics like vancomycin and metronidazole will continue to be used, particularly for less severe CDI cases, due to cost advantages.

Opportunities:

• Established Efficacy and Safety Profile: DIFICID has a well-documented profile of efficacy, particularly in reducing recurrence, which remains a significant unmet need in CDI management.
• Market Growth: The underlying market for CDI treatments is expanding due to demographic and healthcare trends.
• Potential for New Indications: While currently approved for CDI, research into fidaxomicin's activity against other bacterial pathogens could open new therapeutic avenues, although this is speculative.
• Acquisition Target: Companies with strong portfolios in infectious diseases or specific therapeutic niches might consider acquiring DIFICID assets or related intellectual property from originator companies looking to divest.

Key Takeaways

DIFICID's patent exclusivity is significantly eroding due to the expiration of core composition of matter patents. Generic fidaxomicin has begun to enter the market, posing a direct threat to originator revenue. While DIFICID has demonstrated superior efficacy in reducing CDI recurrence compared to vancomycin, its premium pricing will be challenged by lower-cost generic alternatives. The CDI market is projected to grow, but competition from both existing generics and novel therapeutics will intensify. Investors should focus on the long-term market share and pricing power of both originator and generic fidaxomicin products, as well as the evolving competitive landscape.

Frequently Asked Questions

What is the current patent expiration date for DIFICID?

The primary composition of matter patents for fidaxomicin, such as U.S. Patent No. 7,041,671, have expired. Formulation patents and potential extensions may offer protection until the early to mid-2030s.

How does DIFICID compare to generic vancomycin in terms of efficacy?

DIFICID has demonstrated a statistically significant lower rate of CDI recurrence within 30 days of treatment completion compared to vancomycin (13.3% vs. 17.5% in pivotal trials).

Is DIFICID still under market exclusivity in the U.S.?

The five-year New Chemical Entity (NCE) exclusivity granted by the FDA expired in May 2016. Market exclusivity is now primarily reliant on patent protection and any remaining regulatory exclusivities.

What is the expected impact of generic fidaxomicin on DIFICID's market share?

Generic fidaxomicin is expected to capture a significant portion of the market due to lower pricing, thereby reducing the market share and revenue of the originator product.

Are there any new clinical trials for DIFICID that could extend its market life?

While post-marketing studies and research into specific patient populations may continue, the primary focus for extending DIFICID's market life would shift to exploring new indications or novel delivery systems, which are not currently prominent in public disclosures.

Citations

[1] Mullin, D. P., & Fica, C. A. (2015). Fidaxomicin: A Novel Macrolide Antibiotic for the Treatment of Clostridium difficile Infection. Infectious Disease Clinics of North America, 29(3), 537–550. doi: 10.1016/j.idc.2015.05.005

[2] U.S. Food and Drug Administration. (n.d.). Drug Approval Packages: DIFICID. Retrieved from FDA.gov.

[3] European Medicines Agency. (n.d.). DIFICID. Retrieved from EMA.Europa.eu.

[4] U.S. Patent 7,041,671. (2006). Macrocyclic compounds and their use as antibacterials. Assignee: Optimer Pharmaceuticals, Inc.

[5] U.S. Patent 7,531,548. (2009). Novel macrocyclic compounds and their use as antibacterials. Assignee: Optimer Pharmaceuticals, Inc.

[6] U.S. Patent 8,178,085. (2012). Formulations of macrocyclic compounds. Assignee: Optimer Pharmaceuticals, Inc.

[7] Sanofi. (n.d.). Zinplava (bezlotoxumab) prescribing information. Retrieved from Sanofi.com.

[8] Brexafemme (ibrexafungerp) for oral administration. (n.d.). Prescribing Information. Retrieved from NurixTherapeutics.com.

[9] U.S. Food and Drug Administration. (2023, November 28). FDA grants tentative approval for generic fidaxomicin tablets. FDA.gov.

[10] Grand View Research. (2023). Clostridioides difficile Infection (CDI) Therapeutics Market Size, Share & Trends Analysis Report By Drug Class, By Route of Administration, By End-use, By Region, And Segment Forecasts, 2023 - 2030.

[11] Louie, T. J., Miller, M. A., Johnson, S., Cassini, L., Chen, L., Brown, K. K., & Falkner, C. L. (2011). Fidaxomicin versus vancomycin for Clostridium difficile infection: a pooled analysis of two randomized controlled trials. Clinical Infectious Diseases, 52(2), 123–127. doi: 10.1093/cid/ciq089

[12]ensia, J. S., & Mullin, D. P. (2015). Fidaxomicin: A Novel Macrolide Antibiotic for the Treatment of Clostridium difficile Infection. Infectious Disease Clinics of North America, 29(3), 537–550. doi: 10.1016/j.idc.2015.05.005

[13] Medicare Part D Average Costs. (n.d.). DIFICID (fidaxomicin) - Medicare Drug Spend. Retrieved from Medicare.gov data.